Related Experiment Videos
[Medical treatment of diabetic retinopathy]
R Brancato1, F Bandello, P Nucci
1Clinica oculistica, Università, Istituto Scientifico H San Raffaele, Milano.
Abstract:
The pathogenesis of diabetic retinopathy (DR) consists of a complex patch-work of factors correlated and independent on one another at the same time. It is therefore difficult to find pharmaceuticals able to produce different, or even mutually contrasting effects. Another difficulty are the intrinsic characteristics of the disease which after developing to a "critical" stage, evolves with independent mechanism to the most advanced stages. In spite of that, a great deal of medicaments has been suggested so far, all providing therapeutical logic to interfere with one or more pathogenetical stages of the lesions. Although several clinical trials have been performed, survey and follow-up are still limited and insufficient to draw conclusion on the effectiveness of medical therapy. In recent times new types of medicaments such as aldose-reductase inhibitors and carbonic anhydrase-inhibitors have been suggested. The preliminary results present encouraging perspectives for their use, although caution, until long-term results are available with greater surveys and longer follow-up periods, is advised.
Insights
Diabetic retinopathy (DR) treatment is complex due to multifactorial pathogenesis. New drugs like aldose-reductase and carbonic anhydrase inhibitors show promise, but long-term data is needed.
Area of Science:
- Ophthalmology
- Endocrinology
- Pharmacology
Context:
- Diabetic retinopathy (DR) pathogenesis involves complex, interconnected factors.
- The disease progresses independently after a critical stage, complicating treatment.
- Existing treatments target specific pathological pathways with limited success.
Purpose:
- To review current and emerging pharmaceutical interventions for diabetic retinopathy.
- To assess the therapeutic logic and preliminary efficacy of novel drug classes.
Summary:
- DR pathogenesis is complex, hindering the development of effective, multi-target pharmaceuticals.
- Numerous drugs have been proposed, targeting various lesion stages.
- Newer agents, including aldose-reductase and carbonic anhydrase inhibitors, show early promise.
Impact:
- Limited clinical trial follow-up restricts definitive conclusions on current medical therapies.
- Emerging drug classes offer encouraging perspectives but require further long-term validation.
- Future research should focus on extended surveys and follow-up periods for novel DR treatments.